Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes (T2DM) and mild hyperglycemia

被引：0
作者：
Scherbaum, W. A.
Schweizer, A.
Mari, A.
Nilsson, P. M.
Lalanne, G.
Jauffret, S.
Foley, J. E.
机构：
来源：
DIABETES | 2007年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A134 / A134
页数：1
相关论文
共 50 条
[31]   The Safety and Tolerability of Metformin plus Colesevelam in Drug-Naive Patients with Early Type 2 Diabetes Mellitus [J].
Abby, Stacey L. ;
Garvey, W. Timothy ;
Handelsman, Yehuda ;
Fonseca, Vivian A. ;
Goldberg, Ronald B. ;
Rosenstock, Julio ;
Jones, Michael R. ;
Markiewicz, Magdalena ;
Jin, Xiaoping ;
Misir, Soamnauth ;
Nagendran, Sukumar .
DIABETES, 2010, 59 :A173-A173
[32]   Vildagliptin and rosiglitazone demonstrate similar efficacy, tolerability in patients with type 2 diabetes [J].
不详 .
FORMULARY, 2007, 42 (05) :302-303
[33]   Initial combination therapy with vildagliptin plus metformin in drug-naive patients with T2DM: a 24-week real-life study from Asia [J].
Chawla, Manoj ;
Kim, Tae Ho ;
Mirasol, Roberto C. ;
Faruque, Pathan ;
Cooke, Kathryn ;
Hours-Zesiger, Peggy ;
Shete, Abhijit .
CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (09) :1605-1611
[34]   Efficacy and tolerability of the DPP-4 inhibitor vildagliptin in drug naive patients with Type 2 diabetes aged 65 years and older. [J].
Baron, M. A. ;
Schweizer, A. ;
Couturier, A. ;
Dejager, S. .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (04) :S25-S26
[35]   Safety and tolerability of empagliflozin (EMPA) in phase III trials and their extensions in patients with type 2 diabetes (T2DM) [J].
Roden, M. ;
Merker, L. ;
Christiansen, A. V. ;
Roux, F. ;
Hantel, S. ;
Salsali, A. ;
Kim, G. ;
Meinicke, T. ;
Lund, S. S. ;
Hach, T. ;
Woerle, H. J. ;
Broedl, U. C. .
DIABETOLOGIA, 2014, 57 :S325-S326
[36]   Beta-Cell Function and Glycemic Control Following One-Year Vildagliptin Treatment, and after 12-Week Washout, in Drug-Naive Patients with Type 2 Diabetes and Mild Hyperglycemia [J].
Bunck, Mathijs C. ;
Poelma, Marieke ;
Goede, Diane L. ;
Van Golen, Larissa W. ;
Van Genugten, Renate E. ;
Eekhoff, E. Marelise ;
Schweizer, Anja ;
Heine, Robert J. ;
Foley, James E. ;
Nijpels, Giel ;
Diamant, Michaela .
DIABETES, 2010, 59 :A17-A17
[37]   Albuminuria and the prediction of retinopathy in patients with type 2 diabetes (T2DM) [J].
Inzucchi, SE ;
Chyun, DA ;
Young, LH ;
Davey, JA ;
Wittlin, SD ;
Grey, NJ ;
Wackers, FJT .
DIABETES, 2005, 54 :A558-A559
[38]   K-111, a novel non-TZD insulin sensitizer, improves plasma glucose and lipid abnormalities in patients with drug-naive type 2 diabetes mellitus (T2DM) [J].
Yamada, Nobuhiro ;
Akanuma, Yasuo ;
Kawamori, Ryuzo ;
Kasuga, Masato ;
Araki, Eiichi ;
Ohashi, Yasuo .
DIABETES, 2006, 55 :A138-A139
[39]   Efficacy and Tolerability of Vildagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy [J].
Goodman, M. ;
Thurston, H. ;
Penman, J. .
HORMONE AND METABOLIC RESEARCH, 2009, 41 (05) :368-373
[40]   Vildagliptin significantly decreases blood pressure (BP) in hypertensive patients (pts) with type 2 diabetes (T2DM) compared with metformin [J].
Bosi, E. ;
Byiers, S. R. ;
Cohen, S. E. .
DIABETES, 2007, 56 :A139-A139
12345